

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Approval Package for:**

***APPLICATION NUMBER:***

**204251Orig1s000**

***Trade Name:*** Simbrinza Ophthalmic Suspension, 1%/0.2%

***Generic Name:*** Brinzolamide/Brimonidine Tartrate

***Sponsor:*** Alcon Research, Ltd.

***Approval Date:*** 04/19/2013

***Indications:*** Reduction of Elevated Intraocular Pressure in Patients with Open-Angle Glaucoma or Ocular Hypertension.

# CENTER FOR DRUG EVALUATION AND RESEARCH

*APPLICATION NUMBER:*  
**204251Orig1s000**

## CONTENTS

<b>Reviews / Information Included in this NDA Review.</b>
---

<b>Approval Letter</b>	<b>X</b>
<b>Other Action Letters</b>	
<b>Labeling</b>	<b>X</b>
<b>REMS</b>	
<b>Summary Review</b>	<b>X</b>
<b>Officer/Employee List</b>	<b>X</b>
<b>Office Director Memo</b>	
<b>Cross Discipline Team Leader Review</b>	<b>X</b>
<b>Medical Review(s)</b>	<b>X</b>
<b>Chemistry Review(s)</b>	<b>X</b>
<b>Environmental Assessment</b>	
<b>Pharmacology Review(s)</b>	<b>X</b>
<b>Statistical Review(s)</b>	<b>X</b>
<b>Microbiology Review(s)</b>	<b>X</b>
<b>Clinical Pharmacology/Biopharmaceutics Review(s)</b>	<b>X</b>
<b>Other Reviews</b>	<b>X</b>
<b>Risk Assessment and Risk Mitigation Review(s)</b>	
<b>Proprietary Name Review(s)</b>	<b>X</b>
<b>Administrative/Correspondence Document(s)</b>	<b>X</b>

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*

**204251Orig1s000**

**APPROVAL LETTER**



NDA 204251

**NDA APPROVAL**

Alcon Research, Ltd  
Attention: Naj Sharif  
Global Regulatory Project Manager  
6201 South Freeway  
Fort Worth, TX 76134-2099

Dear Mr. Sharif:

Please refer to your New Drug Application (NDA) dated and received June 19, 2012, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act for SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension), 1%/0.2%.

We acknowledge receipt of your amendments dated:

July 3, 2012 (2)	July 27, 2012	August 2, 2012
August 10, 2012	August 21, 2012	October 3, 2012
December 13, 2012	December 14, 2012	December 20, 2012
January 4, 2013	January 11, 2013	January 17, 2013
January 22, 2013	February 15, 2013	February 26, 2013
March 1, 2013	April 3, 2013	April 16, 2013
April 18, 2013		

This new drug application provides for the use of SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2%, for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*, available at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

## **CARTON AND IMMEDIATE-CONTAINER LABELS**

Submit final printed carton and immediate-container labels that are identical to the enclosed carton and immediate-container labels as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008)*. Alternatively, you may submit 12 paper copies, with 6 of the copies individually mounted on heavy-weight paper or similar material. For administrative purposes, designate this submission “**Final Printed Carton and Container Labels for approved NDA 204251.**” Approval of this submission by FDA is not required before the labeling is used.

Marketing the product(s) with FPL that is not identical to the approved labeling text may render the product misbranded and an unapproved new drug.

## **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for ages 0 to < 2 years because there is evidence suggesting that the drug product would be unsafe in this pediatric population; the brimonidine component of your combination drug product is contraindicated in children under the age of 2. This product is appropriately labeled for use in ages 2 to 16 years for this indication. Therefore, no additional studies are needed in this pediatric group.

## **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Prescription Drug Promotion  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Chief, Project Management Staff at 301-796-0763.

Sincerely,

*{See appended electronic signature page}*

Renata Albrecht, MD  
Director  
Division of Transplant and Ophthalmology  
Products  
Office of Antimicrobial Products  
Office of New Drugs  
Center for Drug Evaluation and Research

Enclosure(s): Content of Labeling  
Carton and Container Labels

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

RENATA ALBRECHT  
04/19/2013